PLK1 and neoplasm: Given that onvansertib alone or in combination with other chemotherapeutic agents has shown promising activity in clinical trials and overexpression of Plk1 has been demonstrated in EC, it is logical to investigate the therapeutic effects of onvansertib alone or in combination with other chemotherapeutic agents on cell proliferation and tumor growth in pre-clinical models of EC.